Healthcare Sector Stocks to Watch – Merck & Co., Inc. (NYSE:MRK), Bristol Myers Squibb Co. (NYSE:BMY).
Massapequa Park – April 9, 2013 — (Net PR News) -King Penny Stocks is an elite financial community for investors and traders alike who are looking to potentially gain financial freedom through the markets on undervalued companies and “in-play” momentum penny stocks. Today, we bring a special trend analysis of the following stocks: Merck & Co., Inc. (NYSE:MRK), Bristol Myers Squibb Co. (NYSE:BMY)
PLUS you’ll get KingPennyStock’s Pro Trading Rules Mini E-book absolutely FREE! Claim Your Copy
Trend analysis report of stocks at the Drug Manufacturers Major industry of the Healthcare Sector. Merck & Co., Inc. (NYSE:MRK) remained with higher volume in its industry and showing bullish momentum during previous trade and Bristol Myers Squibb Co. (NYSE:BMY) remained with positive movement and in the news while last trading due to their latest news and sizzling activities.
Merck & Co., Inc. (NYSE:MRK) reported that it will hold, on Wednesday, May 1, 2013, at 8:00 a.m. EDT, first quarter of 2013 sales and earnings conference call with institutional analysts and investors. In the duration of the conference call, the chairman and CEO of MRK, Kenneth C. Frazier, executive vice president and CFO, Peter N. Kellogg and president, Global Human Health, Adam H. Schechter, will provide an overview of the financial performance of the company for the quarter.
Why Should Investors Buy MRK After The Recent Gain? Just Go Here and Find Out
Healthcare Sector stock showing a positive trend during previous trade, Merck & Co., Inc. (NYSE:MRK) ended its day with the gain of 0.78% and closed at the price of $45.48 after opening at $45.09. Stock traded during its last trading session with the total volume of 10.15 million shares, as compared to its average volume of 17.89 million shares.
During the previous session, the company’s minimum price was $44.96, while it touched its highest price for the day at $45.48. MRK’s beta value stands at 0.33 points. During the last one month, the company surged 5.84%, while its last 5 days shows a rise of 2.55%.
Bristol Myers Squibb Co. (NYSE:BMY) declared that, as an executive vice president and chief scientific officer of the company, Francis Cuss, MB BChir, FRCP, 58, has been appointed. This will effective on 1st July.
Drug Manufacturers Major company showing an upward trend during the previous trading session, Bristol Myers Squibb Co. (NYSE:BMY) reported the increase of 0.30% to close at $40.73 with the overall traded volume of 7.20 million shares.
Will BMY Continue To Move Higher? Find Out Here
Bristol Myers Squibb Co. (NYSE:BMY) has the total of 1.64 billion outstanding shares. During last trade, the company’s minimum price was $40.14, while it touched its highest price of $40.74.
Its market capitalization was $66.69 billion. Its beta value stands at 0.475 times and earnings per share was $1.15. Company’s year to date performance remained optimistic with the climb of 24.98%. If we look at the last 6 months of trade, that is in the bullish zone with the rise of 21.36%.
For How Long will BMY’s Gloss Attract Investors? Find out via this report
King Penny Stocks provides up to the minute dissemination of news while reporting on stocks that are actively traded in the small cap arena whether trading on the Nasdaq small caps, AMEX or the OTC markets. Since performance is key in our industry, it’s no wonder why our ground breaking alerts on active stocks have brought us to the forefront of this industry. Our due diligence on trend analysis has caught the attention of the very best chart technicians in the business.
King Penny Stocks is an elite financial community for investors and traders alike who are looking to potentially gain financial freedom through the markets on undervalued companies and “in-play” momentum penny stocks. Get detailed breakdowns of major trends impacting the markets.
Our newsletter, Press Release and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.
An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research. This report/release/advertisement is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation.
Read our Full Disclaimer at: http://kingpennystocks.com/disclaimer/